Amendments to the Claims:

1. (Currently amended) ~~A sterile injectable pharmaceutical composition comprising~~ a pharmaceutically active agent and a buffer, wherein said buffer consists substantially of succinate at a concentration of 7 mM to 45 mM and a counterion, and wherein said pharmaceutically active agent is selected from the group consisting of an insulin-like growth factor I (IGF-I), an interleukin-2, an interferon-β, a fibroblast growth factor (FGF) I, an FGF II, an Epotein-α, a growth hormone, a CNTF, a BNDF, a TPA, a colony-stimulating factor, a peptide, a carbohydrate, a lipid, a fatty acid, a nucleic acid, ampicillin, penicillin, chloroquine hydrochloride, cephalothin, cefamandole, ceforanide, cefotaxime, cefepime, gentamycin, netilmicin, griseofulvin, clotrimazole, miconozole, betamethasone, cortisol, prednisolone, sumatriptan, chlorpheniramine maleate, brompheniramine maleate, enalaprilat, amrinone, dobutamine, and thiethylperazine.

2. (Original) The composition of claim 1, wherein said counterion is selected from the group consisting of: sodium, potassium, ammonium and said pharmaceutically active agent.

3. (Previously presented) The composition of claim 1, wherein the concentration of succinate is 10 mM to 30 mM.

4. (Previously presented) The composition of claim 3, wherein the concentration of succinate is 10 mM to 20 mM.

5. (Previously presented) The composition of claim 4, wherein the concentration of succinate is 10 mM.

6. (Original) The composition of claim 1, wherein said composition has a pH of about 4.0 to 7.0.

7. (Original) The composition of claim 6, wherein said pH is about 4.6-6.6.

8. (Original) The composition of claim 7, wherein said pH is about 6.0.

9. (Previously presented) The composition of claim 1, further comprising a sufficient concentration of a tonicifying agent such that the composition is isotonic.

10. (Original) The composition of claim 9, wherein said tonicifying agent is sodium chloride.

Claims 11-12 (Canceled)

13. (Original) The pharmaceutical composition of claim 1 wherein said composition is a liquid.

14. (Original) The pharmaceutical composition of claim 1 wherein said composition is lyophilized.

15-20 (Canceled)

21. (Original) A pharmaceutical composition comprising human insulin-like growth factor 1 (IGF-I) and a buffer, wherein said buffer consists substantially of succinate at a concentration of about 10 mM to about 40 mM and a counterion.

22. (Original) The composition of claim 21, wherein said counterion is selected from the group consisting of sodium, potassium, ammonium, and said IGF-I.

23. (Original) The composition of claim 21, wherein the concentration of succinate is about 10 mM to about 30 mM.

24. (Original) The composition of claim 23, wherein the concentration of succinate is about 10 mM to about 20 mM.

25. (Original) The composition of claim 24, wherein the concentration of succinate is about 10 mM.

26. (Original) The composition of claim 21, wherein said composition has a pH of about 4.0 to about 7.0.

27. (Original) The composition of claim 26, wherein said pH is about 4.6 to about 6.6.

28. (Original) The composition of claim 27, wherein said pH is about 6.0.

29. (Previously presented) The composition of claim 21, further comprising a sufficient concentration of a tonicifying agent such that the composition is isotonic.

30. (Original) The composition of claim 29, wherein said tonicifying agent is sodium chloride.

31. (Original) The composition of claim 21, wherein said human IGF-I is recombinant human IGF-I.

32. (Original) The composition of claim 31, wherein said composition has a pH of about 6.0, the concentration of said succinate is about 10 mM, and the composition further comprises about 140 mM sodium chloride.

33. (Original) The pharmaceutical composition of claim 21, wherein said composition is a liquid.

34. (Original) The pharmaceutical composition of claim 21, wherein said composition is lyophilized.

35-37 (Canceled)

38. (Previously presented) The composition of claim 1, wherein the concentration of succinate is 8 mM to 40 mM.

39. (Previously presented) The composition of claim 38, wherein the concentration of succinate is 9 mM to 40 mM.

40. (Previously presented) The composition of claim 38, wherein the concentration of succinate is 10 mM to 40 mM.

Claims 41-44 (Canceled)

03

45. (New) A sterile injectable pharmaceutical composition comprising human insulin-like growth factor I (IGF-I) or a biologically active variant thereof and a buffer, wherein said buffer consists substantially of succinate at a concentration of 7 mM to 45 mM and a counterion, wherein said variant is a polypeptide having IGF-I activity and at least 70% sequence identity to human IGF-I.

46. (New) The composition of claim 45, wherein said composition has a pH of about 6.0, the concentration of said succinate is about 10 mM, and the composition further comprises about 140 mM sodium chloride.

47. (New) A sterile injectable non-sustained-release pharmaceutical composition comprising a pharmaceutically active agent and a buffer, wherein said buffer consists substantially of succinate at a concentration of 7 mM to 45 mM and a counterion.

48. (New) The composition of claim 47, wherein said counterion is selected from the group consisting of: sodium, potassium, ammonium and said pharmaceutically active agent.

49. (New) The composition of claim 47, wherein the concentration of succinate is 10 mM to 40 mM.

50. (New) The composition of claim 47, wherein said composition has a pH of about 4.0 to 7.0.

51. (New) The composition of claim 47, further comprising a sufficient concentration of a tonicifying agent such that the composition is isotonic.

52. (New) The composition of claim 51, wherein said tonicifying agent is sodium chloride.